The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma

Annals of Oncology

Volumn 27, Issue 8, 2016, Pages 1467-1474

  Wirth, T C ^a   Manns, Michael P ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b German Center for Infectious Diesease (DZIF)   (Germany)

Author keywords

Antiviral therapy; Cirrhosis; Decompensated liver function; Hepatitis C; Hepatocellular carcinoma; Liver transplantation

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DASABUVIR; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; VELPATASVIR;

ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CHILD PUGH SCORE; CLINICAL TRIAL (TOPIC); COMPENSATED LIVER CIRRHOSIS; DECOMPENSATED LIVER CIRRHOSIS; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; VIRAL CLEARANCE; COMPLICATION; HEPACIVIRUS; LIVER; LIVER TUMOR; PATHOGENICITY; PATHOLOGY; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER; LIVER NEOPLASMS;

EID: 84984993543     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw219     Document Type: Article

References (94)

1. Chung RT, Baumert TF. Curing chronic hepatitis C-the arc of a medical triumph. N Engl J Med 2014; 370: 1576-1578.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.
3. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342.
4. Choo QL, Kuo G, Weiner AJ et al. Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362.
5. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013; 19: 837-849.
6. Ghany MG, Liang TJ. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013; 369: 679-680.
7. Manns MP, von Hahn T. Novel therapies for hepatitis C-one pill fits all? Nat Rev Drug Discov 2013; 12: 595-610.
8. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol 2014; 28: 753-770.
9. Park JW, Chen M, Colombo M et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015; 35: 2155-2166.
10. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255.
11. Hong T, Gow P, Fink M et al. Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed. Hepatology 2016; 63(4): 1205-1212.
12. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000; 160: 3227-3230.
13. Davis GL, Alter MJ, El-Serag H et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521, 521.e511-516.
14. Hirschfield GM, Thain C, Walmsley M et al. Liver disease in the UK. Lancet 2015; 385: 503.
15. Kudo M. Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer 2015; 4: 39-50.
16. Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol 1999; 31(Suppl 1): 17-24.
17. Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 2010; 32: 344-355.
18. Fattovich G, Pantalena M, Zagni I et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002; 97: 2886-2895.
19. Kobayashi M, Ikeda K, Hosaka T et al. Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol 2006; 78: 459-465.
20. Toshikuni N, Izumi A, Nishino K et al. Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis. J Gastroenterol Hepatol 2009; 24: 1276-1283.
21. D'Ambrosio R, Aghemo A, Rumi MG et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012; 56: 532-543.
22. Perz JF, Armstrong GL, Farrington LA et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538.
23. Sangiovanni A, Prati GM, Fasani P et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-1310.
24. van der Meer AJ, Hansen BE, Fattovich G et al. Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. Gut 2015; 64: 322-331.
25. Sanyal AJ, Banas C, Sargeant C et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 43: 682-689.
26. Bruix J, Poynard T, Colombo M et al. Maintenance therapy with peginterferon alfa- 2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology 2011; 140: 1990-1999.
27. Di Bisceglie AM, Shiffman ML, Everson GT et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 2429-2441.
28. Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313.
29. Mallet V, Gilgenkrantz H, Serpaggi J et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149: 399-403.
30. McCombs J, Matsuda T, Tonnu-Mihara I et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med 2014; 174: 204-212.
31. van der Meer AJ, Veldt BJ, Feld JJ et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593.
32. Charlton M, Everson GT, Flamm SL et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649-659.
33. Curry MP, O'Leary JG, Bzowej N et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015; 373: 2618-2628.
34. Deterding K, Honer Zu Siederdissen C, Port K et al. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Aliment Pharmacol Ther 2015; 42: 889-901.
35. Honer Zu Siederdissen C, Maasoumy B, Deterding K et al. Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting. Liver Int 2015; 35: 1845-1852.
36. Manns M, Samuel D, Gane EJ et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016, pii: S1473-3099(16)00052-9.
37. Poordad F, Schiff ER, Vierling JM et al. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology 2016; 63(5): 1493-1505.
38. van der Meer AJ, Veldt BJ, Feld JJ et al. The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. J Viral Hepat 2014; 21: 568-577.
39. Gambato M, Lens S, Navasa M, Forns X. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. J Hepatol 2014; 61: S120-S131.
40. Ohkoshi S, Hirono H, Yamagiwa S. Direct antiviral agent treatment of decompensated hepatitis C virus-induced liver cirrhosis. World J Gastrointest Pharmacol Ther 2015; 6: 114-119.
41. Verna EC, Shetty K, Lukose T et al. High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitorbased triple therapy. Liver Int 2015; 35: 510-517.
42. Younossi ZM, Stepanova M, Henry L et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol 2014; 60: 741-747.
43. Dyson JK, Hutchinson J, Harrison L et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol 2016; 64: 234-238.
44. Petrick JL, Kelly SP, Altekruse SF et al. Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J Clin Oncol 2016; 34: 1787-1794.
45. Ikeda K, Arase Y, Saitoh S et al. Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts. J Hepatol 2006; 44: 1089-1097.
46. Lee MH, Yang HI, Lu SN et al. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol 2010; 28: 4587-4593.
47. Nishiguchi S, Kuroki T, Nakatani S et al. Randomised trial of effects of interferonalpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.
48. Cardoso AC, Moucari R, Figueiredo-Mendes C et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52: 652-657.
49. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2001; 15: 689-698.
50. Singal AK, Singh A, Jaganmohan S et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010; 8: 192-199.
51. Morgan RL, Baack B, Smith BD et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158: 329-337.
52. Aleman S, Rahbin N, Weiland O et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 2013; 57: 230-236.
53. Toyoda H, Tada T, Tsuji K et al. Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: a multicenter study from Japan. Hepatol Res 2015.
54. Chang KC, Hung CH, Lu SN et al. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. J Antimicrob Chemother 2012; 67: 2766-2772.
55. Asahina Y, Tsuchiya K, Nishimura T et al. alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 2013; 58: 1253-1262.
56. Nagaoki Y, Aikata H, Nakano N et al. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: a large-scale, long-term cohort study. J Gastroenterol Hepatol 2016; 31(5): 1009-1015.
57. Sasaki Y, Yamada T, Tanaka H et al. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma. Ann Surg 2006; 244: 771-780.
58. Toshikuni N, Takuma Y, Goto T, Yamamoto H. Prognostic factors in hepatitis C patients with a single small hepatocellular carcinoma after radiofrequency ablation. Hepatogastroenterology 2012; 59: 2361-2366.
59. Nojiri S, Kusakabe A, Shinkai N et al. Factors influencing distant recurrence of hepatocellular carcinoma following combined radiofrequency ablation and transarterial chemoembolization therapy in patients with hepatitis C. Cancer Manag Res 2011; 3: 267-272.
60. Wahab MA, Shehta A, Hamed H et al. Predictors of recurrence in hepatitis C virus related hepatocellular carcinoma after hepatic resection: a retrospective cohort study. Eurasian J Med 2014; 46: 36-41.
61. Kakizaki S, Sohara N, Sato K et al. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J Gastroenterol Hepatol 2007; 22: 518-522.
62. Nishikawa H, Osaki Y, Iguchi E et al. The effect of long-term supplementation with branched-chain amino acid granules in patients with hepatitis C virusrelated hepatocellular carcinoma after radiofrequency thermal ablation. J Clin Gastroenterol 2013; 47: 359-366.
63. Ikeda K, Arase Y, Saitoh S et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32: 228-232.
64. Mazzaferro V, Romito R, Schiavo M et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44: 1543-1554.
65. Singal AK, Freeman DH, Jr., Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 32: 851-858.
66. Xu J, Li J, Chen J, Liu ZJ. Effect of adjuvant interferon therapy on hepatitis B/C virus-related hepatocellular carcinoma after curative therapy-meta-analysis. Adv Clin Exp Med 2015; 24: 331-340.
67. Zhang W, Song TQ, Zhang T et al. Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: a meta-analysis with comparison of different types of hepatitis. Mol Clin Oncol 2014; 2: 1125-1134.
68. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 2010; 17: 287-292.
69. Shen YC, Hsu C, Chen LT et al. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol 2010; 52: 889-894.
70. Huang TS, Shyu YC, Chen HY et al. A systematic review and meta-analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitisrelated hepatocellular carcinoma. J Viral Hepat 2013; 20: 729-743.
71. Kanogawa N, Ogasawara S, Chiba T et al. Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. J Gastroenterol Hepatol 2015; 30: 1197-1204.
72. Hsu YC, Ho HJ, Wu MS et al. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatology 2013; 58: 150-157.
73. Harada N, Hiramatsu N, Oze T et al. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma-a retrospective multicenter study. J Med Virol 2015; 87: 1199-1206.
74. Shirabe K, Sugimachi K, Harada N et al. Favorable prognosis in patients with sustained virological response to antiviral therapy, including interferon, for chronic hepatitis C before hepatic resection for hepatocellular carcinoma. Anticancer Res 2015; 35: 6963-6969.
75. Saito T, Chiba T, Suzuki E et al. Effect of previous interferon-based therapy on recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Med Sci 2014; 11: 707-712.
76. Jimenez-Perez M, Gonzalez-Grande R, Rando-Munoz FJ. Management of recurrent hepatitis C virus after liver transplantation. World J Gastroenterol 2014; 20: 16409-16417.
77. Berenguer M, Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol 2013; 58: 1028-1041.
78. Dumitra S, Alabbad SI, Barkun JS et al. Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20-year experience. HPB (Oxford) 2013; 15: 724-731.
79. Curry MP, Forns X, Chung RT et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015; 148: 100-107.e1.
80. Charlton M, Gane E, Manns MP et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108-117.
81. Kwo PY, Mantry PS, Coakley E et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371: 2375-2382.
82. Brown RS, Jr., O'Leary JG, Reddy KR et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real world experience from HCV-TARGET. Liver Transpl 2016; 22(1): 24-33.
83. Forns X, Charlton M, Denning J et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 2015; 61: 1485-1494.
84. Righi E, Londero A, Carnelutti A et al. Impact of new treatment options for hepatitis C virus infection in liver transplantation. World J Gastroenterol 2015; 21: 10760-10775.
85. Samuel D, Duclos-Vallee JC. Liver transplantation: the effect of new HCV drugs on liver transplantation outcomes. Nat Rev Gastroenterol Hepatol 2015; 12: 559-560.
86. Ferenci P. Treatment of hepatitis C in difficult-to-treat patients. Nat Rev Gastroenterol Hepatol 2015; 12: 284-292.
87. Pungpapong S, Aqel B, Leise M et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015; 61: 1880-1886.
88. Saab S, Greenberg A, Li E et al. Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients. Liver Int 2015; 35: 2442-2447.
89. Russo FP, Zanetto A, Burra P. Timing for treatment of HCV recurrence after liver transplantation: the earlier the better. Transpl Int 2015.
90. Durham DP, Skrip LA, Bruce RD et al. The impact of enhanced screening and treatment on hepatitis C in the United States. Clin Infect Dis 2016; 62: 298-304.
91. Harris RJ, Thomas B, Griffiths J et al. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios. J Hepatol 2014; 61: 530-537.
92. Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology 2012; 55: 1652-1661.
93. Moorman AC, Xing J, Ko S et al. Late diagnosis of hepatitis C virus infection in the Chronic Hepatitis Cohort Study (CHeCS): missed opportunities for intervention. Hepatology 2015; 61: 1479-1484.
94. Reig M, Marino Z, Perello C et al. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 2016, pii: S0168-8278(16) 30113-1.